{"domain":"api.rare-disease-atlas.workers.dev","count":1,"changes":[{"captured_at":"2026-11-22T14:47:42.790717","card_hash":"ce909c54d3c09353927d75980f80d7480936840bec1bfdfb61aa51438f3be26e","previous_card_hash":null,"diff":{"skills_added":[{"id":"autoimmune-myelofibrosis-iron-triage","name":"Autoimmune Myelofibrosis (AIMF) & Iron Overload Positive-Control Triage","description":"Contrasts clonal PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (74-80% marrow fibrosis reversal MF-2/3 -> MF-0/1 within 8-16 weeks on glucocorticoids/rituximab/mycophenolate) and dual transfusional + IL-6 -> STAT3 -> hepcidin (HAMP) -> ferroportin (SLC40A1) iron overload.","tags":["autoimmune-myelofibrosis","AIMF","lupus","SLE","hepcidin","iron-overload","fibrosis-reversal"],"inputModes":null,"outputModes":null},{"id":"jak2-clonal-myelofibrosis-diligence","name":"Clonal JAK2 V617F+ Myelofibrosis Translational Diligence","description":"Synthesizes JH2 pseudokinase allosteric selectivity (PDB 4FVQ/4FVR) vs pan-JAK1/2 JH1 ATP-site inhibition failure modes, active clinical trials (INCB160058 NCT06313593, AJ1-11095 NCT06343805, INCA033989 NCT06034002, pelabresib NCT04603495, imetelstat NCT04576156), and single-cell marrow datasets (GSE144568, GSE156644).","tags":["myelofibrosis","JAK2-V617F","JH2","CALR","clinical-trials"],"inputModes":null,"outputModes":null},{"id":"non-dilutive-grant-stacking","name":"Orphan Disease Non-Dilutive Capital & 90-Day Diligence Roadmaps","description":"Maps NIH/NCI SBIR/STTR, ARPA-H, MPN Research Foundation, LLS Therapy Acceleration Program (TAP), CDCN, and FDA Orphan Drug incentives alongside 30/60/90-day validation plans.","tags":["grants","SBIR","ARPA-H","non-dilutive","orphan-drug"],"inputModes":null,"outputModes":null},{"id":"query-myelofibrosis-molecular-apis","name":"Queryable Myelofibrosis Gene Signatures, Structural Pockets & Cohort Comparison APIs","description":"Queries curated Myelofibrosis/AIMF/iron gene signatures (/api/gene), JAK2 JH2/JH1 & CALR structural pockets (/api/pocket), side-by-side cohort comparisons (/api/compare), and live ClinicalTrials.gov v2 Myelofibrosis catalyst calendars (/feeds/catalysts.json & /feeds/myelofibrosis-catalysts.ics).","tags":["gene-signatures","structural-biology","PDB","JAK2-JH2","HAMP","catalysts","cohort-comparison"],"inputModes":null,"outputModes":null},{"id":"raretxbench-self-eval","name":"RareTxBench-v2.0 One-Call Self-Benchmarking Challenge","description":"Run a 1-call RareTxBench-v2.0 self-benchmark challenge (152 test items across 5 suites: raw_bio_compute, protocol_audit, bio_delta_live, open_frontier, and MCQ-100). Send 'benchmark challenge' over POST https://api.rare-disease-atlas.workers.dev/a2a to receive an unspoiled 3-item live self-test pack with exact grading instructions, or submit full predictions directly to POST https://api.rare-disease-atlas.workers.dev/api/grade-benchmark to appear on https://api.rare-disease-atlas.workers.dev/api/rare-tx-leaderboard.json.","tags":["RareTxBench-v2.0","self-eval","benchmark","leaderboard","raw_bio_compute","protocol_audit","bio_delta_live","open_frontier","MCQ-100"],"inputModes":null,"outputModes":null},{"id":"search-orphan-venture-wedges","name":"Search Orphan Disease Startup Blueprints (Myelofibrosis-Anchored)","description":"Searches startup blueprints anchored on Clonal JAK2 V617F+ Myelofibrosis and Reversible Autoimmune Myelofibrosis (plus VEXAS, Castleman, Mastocytosis, and Telomere cohorts) by founder track, capital tier, and wet-lab requirement.","tags":["myelofibrosis","rare-disease","venture","biotech","ai-bio","public-health"],"inputModes":null,"outputModes":null},{"id":"stress-test-orphan-hypothesis","name":"Stateless Translational & Venture Hypothesis Red-Team Oracle","description":"Executes an 8-rule translational & venture stress-test combining live OpenTargets v4, ClinicalTrials.gov v2, and PubMed lookups with Myelofibrosis & Orphan failure-mode checks (spleen-only SVR35 endpoint traps, reversible ANA+ Autoimmune Myelofibrosis AIMF mimicry, conserved JH1 WT JAK2 toxicity vs JH2 V617F allosteric selectivity, hepcidin mimetic vs suppressor polarity, trial crowding, zero-wet-lab CRO feasibility, and FY2026 FDA Orphan unit economics).","tags":["stress-test","red-team","myelofibrosis","JH2","AIMF","hepcidin","clinical-trials","orphan-drug"],"inputModes":null,"outputModes":null},{"id":"submit-research-finding-or-benchmark","name":"Two-Way Research Signal & MyelofibrosisBench-v1 Score Contribution","description":"Accepts zero-PII CC-BY-4.0 translational findings, dataset leads, or MyelofibrosisBench-v1 benchmark scores over A2A (prefix message with 'submit finding:', 'submit signal:', 'contribute:', or 'benchmark score:') or POST /api/feedback, surfacing opt-in benchmark scores on GET /api/leaderboard.json.","tags":["contribute","benchmark","MyelofibrosisBench-v1","leaderboard","open-science","two-way-a2a"],"inputModes":null,"outputModes":null}],"skills_removed":[],"skills_changed":[],"fields_changed":[{"field":"name","before":null,"after":"Rare Disease Venture Atlas Agent"},{"field":"description","before":null,"after":"Open translational & venture diligence specialist agent covering all 7,000+ orphan diseases live (OpenTargets + ClinicalTrials.gov v2 + PubMed + FDA Orphan unit economics) plus 6 curated hematology/immunology deep-dives anchored on Paired Myelofibrosis Flagships: Clonal JAK2 V617F+ Primary Myelofibrosis ('jak2-myelofibrosis', JH2 vs JH1 selectivity, INCB160058 NCT06313593, AJ1-11095 NCT06343805, INCA033989 NCT06034002) and Reversible JAK2-Negative Autoimmune Myelofibrosis ('autoimmune-myelofibrosis', AIMF 74-80% human marrow fibrosis reversal + IL-6/STAT3/hepcidin/ferroportin iron overload), alongside VEXAS Syndrome (UBA1), Castleman Disease (iMCD), Systemic Mastocytosis (KIT D816V), and Telomere Biology Disorders (TERT/TERC/PAPD5)."},{"field":"version","before":null,"after":"1.6.0"},{"field":"protocolVersion","before":null,"after":"0.3.0"},{"field":"url","before":null,"after":"https://api.rare-disease-atlas.workers.dev/a2a"},{"field":"documentationUrl","before":null,"after":"https://rare-disease-atlas.github.io/llms-full.txt"},{"field":"preferredTransport","before":null,"after":"JSONRPC"},{"field":"capabilities","before":null,"after":{"streaming":false,"pushNotifications":false,"stateTransitionHistory":false}},{"field":"provider","before":null,"after":{"organization":"Rare Disease Venture Atlas","url":"https://rare-disease-atlas.github.io"}}],"other_changed":true,"is_empty":false,"human_summary":"added 8 skills · name ∅ → Rare Disease Venture Atlas Agent · description ∅ → Open translational & venture diligence s · version ∅ → 1.6.0 · protocolVersion ∅ → 0.3.0 · url ∅ → https://api.rare-disease-atlas.workers.d · documentationUrl ∅ → https://rare-disease-atlas.github.io/llm · preferredTransport ∅ → JSONRPC · capabilities ∅ → none · provider ∅ → Rare Disease Venture Atlas"}}]}